LFCR Quote, Financials, Valuation and Earnings

Inspire Medical Systems, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of 4.42%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 4.88%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $130.20 which suggests that it could grow by 60.09%. Given that Inspire Medical Systems, Inc. has higher upside potential than Lifecore Biomedical, Inc., analysts believe Inspire Medical Systems, Inc. is more attractive than Lifecore Biomedical, Inc..

Lifecore Biomedical, Inc. has a beta of 0.591, which suggesting that the stock is 40.877% less volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.474%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Inspire Medical Systems, Inc.'s PE ratio is 55.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.38x versus 2.77x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings Corp. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of 8.5%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Integer Holdings Corp.'s return on equity of 5.26%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 4.88%. On the other hand Integer Holdings Corp. has an analysts' consensus of $85.57 which suggests that it could fall by -0.78%. Given that Lifecore Biomedical, Inc. has higher upside potential than Integer Holdings Corp., analysts believe Lifecore Biomedical, Inc. is more attractive than Integer Holdings Corp..

Lifecore Biomedical, Inc. has a beta of 0.591, which suggesting that the stock is 40.877% less volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.493%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Integer Holdings Corp. quarterly revenues of $466.6M. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Integer Holdings Corp.'s net income of $39.7M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Integer Holdings Corp.'s PE ratio is 36.11x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.38x versus 1.67x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Molina Healthcare, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of 0.69%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat Molina Healthcare, Inc.'s return on equity of 19.74%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 4.88%. On the other hand Molina Healthcare, Inc. has an analysts' consensus of $186.69 which suggests that it could fall by -7.14%. Given that Lifecore Biomedical, Inc. has higher upside potential than Molina Healthcare, Inc., analysts believe Lifecore Biomedical, Inc. is more attractive than Molina Healthcare, Inc..

Lifecore Biomedical, Inc. has a beta of 0.591, which suggesting that the stock is 40.877% less volatile than S&P 500. In comparison Molina Healthcare, Inc. has a beta of 0.491, suggesting its less volatile than the S&P 500 by 50.861%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Molina Healthcare, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. Molina Healthcare, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are smaller than Molina Healthcare, Inc. quarterly revenues of $11.5B. Lifecore Biomedical, Inc.'s net income of -$10M is lower than Molina Healthcare, Inc.'s net income of $79M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while Molina Healthcare, Inc.'s PE ratio is 12.46x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.38x versus 0.25x for Molina Healthcare, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -32.12% compared to Lifecore Biomedical, Inc.'s net margin of -255.85%. Lifecore Biomedical, Inc.'s return on equity of -70.33% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Lifecore Biomedical, Inc. has a consensus price target of $9.25, signalling upside risk potential of 4.88%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -73.02%. Given that Lifecore Biomedical, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Lifecore Biomedical, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Lifecore Biomedical, Inc. has a beta of 0.591, which suggesting that the stock is 40.877% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.093, suggesting its less volatile than the S&P 500 by 90.725%.

Lifecore Biomedical, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Lifecore Biomedical, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Lifecore Biomedical, Inc. quarterly revenues are $31.1M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Lifecore Biomedical, Inc.'s net income of -$10M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Lifecore Biomedical, Inc.'s price-to-earnings ratio is 133.20x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 5.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lifecore Biomedical, Inc. is 2.38x versus 6.12x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.